Skip to content

Serotonin, Serotonin Genetics(TPH2) and Emotion and Interference Processing

The Influence of Acute Tryptophan Depletion on Emotion and Interference Processing and Potential Moderation by 5HT Genetics (TPH2)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03549182
Enrollment
50
Registered
2018-06-07
Start date
2017-03-01
Completion date
2021-12-01
Last updated
2020-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

acute tryptophan depletion, tryptophan hydroxylase 2 gene, emotion

Brief summary

The study aims to explore whether acute tryptophan depletion can affect the emotion and interference processing whether this effect is moderated by the TPH2 genotype

Detailed description

Based on previous studies suggesting that serotonin, a neurotransmitter, is associated with social & emotional behavior, including emotional reactivity and emotion regulation, the present study aims to explore effects of acute tryptophan depletion (ATD) on emotion processing and emotional interference processing within a randomized double-blind, with-subject, placebo-controlled pharmaco-fMRI experiment. To further examine the potential moderating effects of the genetic makeup of the serotonin system the present study will include a pharmacogenetics imaging approach. Given that TPH2 is the key regulator of the serotonergic signaling pathway, we therefore assessed whether such the effects of tryptophan depletion vary according to the TPH2 genotype. To this end, healthy male TPH2-GG or TPH2-TT carriers will be recruited and will receive ATD (100g) and placebo (102.3g) in a within subject design. To control for potential effects of pre-medication personality traits as well as effects of medicines on mood, subjects will be administered pre-treatment assessing relevant personality traits and post-treatment assessments of mood.

Interventions

oral administration of ATD (100g)(Acute Tryptophan Depletion)

DRUGplacebo treatment

oral administration of placebo (102.3g)

Sponsors

University of Electronic Science and Technology of China
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
MALE
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy subjects without past or current psychiatric or neurological disorders * Right-handedness

Exclusion criteria

* History of head injury; * Medical or psychiatric illness. * High blood pressure, general cardio-vascular alterations * History of drug or alcohol abuse or addiction. * Allergy against medications or general strong allergies * Sleep disorders. * Visual or motor impairments

Design outcomes

Primary

MeasureTime frameDescription
Neural processing during emotion processing as assessed via fMRI5-6h after administration of ATD, or placeboSubjects will undergo a validated emotional face paradigm. To assess genotype x ATD interaction effects on neural emotional reactivity effects of ATD depletion on the corresponding neural activity will be compared between the TPH2 genotype groups.
Neural processing during interference processing as assessed via fMRI5-6h after administration of ATD, or placeboSubjects will undergo a validated cognitive-emotional interference paradigm. To assess genotype x ATD interaction effects on neural interference control effects of ATD depletion on the corresponding neural activity will be compared between the TPH2 genotype groups.
Neural processing during the resting state as assessed via fMRI5-6h after administration of ATD, or placeboSubjects will undergo a validated resting state assessment. To assess genotype x ATD interaction effects on intrinsic brain activity in the emotion and interreference related neural networks effects of ATD depletion on the corresponding neural activity will be compared between the TPH2 genotype groups.

Secondary

MeasureTime frameDescription
Behavioral interference performance5-6h after administration of ATD, or placeboSubjects will undergo a emotion-cognition interference paradigm. To assess genotype x ATD interaction effects on behavioral indices of interference (congruent vs incongruent trials) behavioral performance (accuracy/reaction time) effects of ATD depletion on the corresponding behavioral indices will be compared between the TPH2 genotype groups.

Countries

China

Contacts

Primary ContactBenjamin Becker, Dr.
ben_becker@gmx.de86-28-61830988

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026